A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08)

NCT07640789 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

418

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer Stage III

Interventions

DRUG: BL-B01D1
DRUG: Osimertinib

Sponsor

Sichuan Baili Pharmaceutical Co., Ltd.

Collaborators

[object Object]